Figure 1.Prognostic relevance of genomic alterations in patients with pancreatic cancer. (A) Kaplan-Meier plots demonstrated the prognostic effects of KRAS, TP53, CDKN2A and SMAD4 alterations in patients with pancreatic cancer in TCGA PAAD datasets. The log-rank test was used to determine the different overall survival between patients with (red) or without (blue) genomic alterations. (B) Univariate and multivariate cox regression were used to test the prognostic significance of KRAS, TP53, CDKN2A and SMAD4 alterations in patients with pancreatic cancer in TCGA PAAD datasets. The log-rank test was used to determine the overall survival P-value. HR, hazard ratio; CI, confidence interval.
